Skip to main content

Potent Anticancer and mTOR Inhibitor Activities of Some Synthesized Linear and Macrocyclic Pyridine Derivatives

Buy Article:

$107.14 + tax (Refund Policy)

A series of linear and macrocyclic 2,6-disubstituted pyridine derivatives 1–7 were previously prepared and evaluated as analgesic and anticonvulsant agents. Herein these derivatives were screened as anti pancreatic cancer, anti-GIT cancer and mTOR inhibitor activities. The tested compounds were found to have in vivo and in vitro potent anti-pancreatic cancer and anti-GIT cancer activities. The mechanism of action of these compounds was evaluated as mTOR inhibitors.

Keywords: 2,6-Disubstituted Pyridine; Anti-GIT Cancer; Anti-Pancreatic Cancer; Leniar and Macrocyclics Derivatives; mTOR Inhibitors

Document Type: Research Article

Affiliations: 1: Pharmaceutical Chemistry Department, Drug Exploration and Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia 2: Research Unit, Saco Pharm. Co., 6th October City 11632, Egypt

Publication date: 01 January 2017

More about this publication?
  • Journal of Computational and Theoretical Nanoscience is an international peer-reviewed journal with a wide-ranging coverage, consolidates research activities in all aspects of computational and theoretical nanoscience into a single reference source. This journal offers scientists and engineers peer-reviewed research papers in all aspects of computational and theoretical nanoscience and nanotechnology in chemistry, physics, materials science, engineering and biology to publish original full papers and timely state-of-the-art reviews and short communications encompassing the fundamental and applied research.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content